trial

tDCS Combined With rTMS for Negative Symptoms of Schizophrenia

NCTId NCT05695144
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 120 (estimated)
Sponsored by Tianjin Anding Hospital
Primary completion 2024-09-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
120 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2022-07-01
Primary completion
2024-09-01
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
tDCS active stimulation combined with rTMS active stimulation

Sponsors

Tianjin Anding HospitalLead Sponsor
Chinese Academy of SciencesCollaborator

Investigators

1
Shen Li, DoctorPrincipal Investigator

Sites

1 total
Tianjin, China

Facts & assertions

4 sourced
Enrollment
120
Phase
NA
Primary Completion Date
2024-09-01
Status
UNKNOWN
relationships
The graph out of here
drug
tDCS active stimulation combined with rTMS active stimulation
drug
lead_sponsor
Tianjin Anding Hospital
company
collaborator
Chinese Academy of Sciences
company
indication
Schizophrenia Negative Type
indication
investigator
Shen Li, Doctor
person